Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients

Inclusion Criteria: * Patient having received of a heart transplant (exclusively) less than 2 weeks before the inclusion date or planned to receive it within days following inclusion. * Patient at least 18 years old, male or female. * Patient treated with one of the following combination : cyclosporine-mycophenolate, tacrolimus-mycophenolate or everolimus- "low-dose" cyclosporine for at least 3 days, and at least 24 hours by the oral route at the time of the first sampling day (between 7 and 15 days post-transplant). * Patient included or not in another study, in particular in a therapeutic trial (e.g. comparison between drug combinations). * Patient having given written informed consent for his/her participation to the trial. Exclusion Criteria: * Patients in disagreement with the present trial. * Patients suffering from neuro-psychic problems, making them unable to well-understand the protocol or to give a reliable consent. * Patients with previous heart or any other solid organ transplantation. * Patients with double transplantation (heart-lung, heart-kidney or heart-liver) * Patients still intubated and ventilated 15 days post-transplant. * Patients with anaemia between Day 7 and 15, as characterized by hematocrit \< 30% or haemoglobin \< 9 g/dl.